Lansoprazole

Lansoprazole (pronounced [lænˈsoʊprəzoʊl], lan-SOE-pra-zole, INN) is a proton pump inhibitor which prevents the stomach from producing acid. It is manufactured by a number of companies worldwide under several brand names (some brand names include: Prevacid, Helicid, Zoton, Inhibitol). It was first approved by the FDA in 1995. Prevacid patent protection expires on Nov. 10, 2009.

Pharmacology

Lansoprazole is a proton pump inhibitor (PPI) in the same pharmacologic class as omeprazole. Lansoprazole has been marketed for many years and is one of several PPIs available.

Lansoprazole's plasma elimination half-life is not proportional to the duration of the drug's effects (i.e. gastric acid suppression). The mean plasma elimination half-life is 1.5 hours, and the effects of the drug last for over 24 hours after it has been used for 1 day or more.

Indications

Lansoprazole is indicated for: Treatment of ulcers of the stomach and duodenum, and NSAID-induced ulcers
Treatment of gastroesophageal reflux disease (GERD) (also known as acid reflux disease)
Treatment of Zollinger-Ellison Syndrome
Adjunctive treatment of Helicobacter pylori infection, alongside antibiotics

Drug Interactions

PPIs reduce absorption of antifungals (itraconazole and ketoconazole) and possibly increase Digoxin in plasma
Increases plasma concentrations of Cilostazol (risk of toxicity)
Absorption of lansoprazole possibly reduced by:
sucralfate
ampicillin
bisacodyl
delavirdine
fluvoxamine
iron salts
theophylline
voriconazole
aminophylline and theophylline
astemizole

Side effects

Infrequent: dry mouth, insomnia, drowsiness, blurred vision, rash, pruritus
Rarely and very rarely: taste disturbance, liver dysfunction, peripheral oedema, hypersensitivity reactions (including bronchospasm, urinary, angioedema, anaphylaxis), photosensitivity, fever, sweating, depression, interstitial nephritis, blood disorders (including leukopenia, leukocytosis, pancytopenia, thrombocytopenia), arthralgia, myalgia, skin reactions (including Stevens-Johnson syndrome, toxic epidermal necrolysis, bullous eruption)
Severe: Gastro-intestinal disturbances (such as nausea 1.3%, abdominal pain 2.1%, diarrhea 3.8%).

Proton pump inhibitors may be associated with a greater risk of hip fractures, clostridium difficile-associated diarrhea. Patients are frequently administered the drugs in intensive care as a protective measure against ulcers, but this use is also associated with a 30% increase in occurrence of pneumonia.

Brand names

The drug is sold under several brand names, including: Agopton (Germany)
Aprazol (Turkey)
Digest (Indonesia)
Duogast (Syria)
Lanpro (India)
Lanzol (India)
Lanzul (Slovenia)
Lansoptol (Hungary)
Lansox (Italy)
Lansoloc (South Africa)
Lanton (Israel)
Lanzor (France)
Laprazol (Greece)
Lanciprol (Greece)
Limpidex (Italy)
Monolitum (Spain)
Ogast and OgastORO (France)
Ogastro (Mexico)
Prevacid (U.S. and Canada) Prevacid is a product of Takeda Pharmaceuticals.
pro-ulco (Spain)
Prosogan and Prosogan FD (Indonesia)
Refluxon (Hungary)
SOLOX (New Zealand)
Takepron (Japan)
Zoton (Italy, Ireland, Australia, UK)
ZOMEL (Ireland)

Lansoprazole is also available as a generic drug in the UK, Canada, Belgium, France, Colombia, Italy and Mexico.

Translation of "Lansoprazole"

Spanish: Lansoprazol, Italian: Lansoprazolo, Hungarian: Lansoprazol, Dutch: Lansoprazol, Japanese: ランソプラゾール, Polish: Lanzoprazol, Portuguese: Lansoprazol, Russian: Лансопразол, Swedish: Lansoprazol, Turkish: Lansoprazol.